18F-rhPSMA-7 PET/CT检测根治性放疗后前列腺癌生化复发:一项双中心回顾性研究
这项双中心回顾性分析评估了新型治疗诊断性前列腺特异性膜抗原(PSMA)靶向配体18F-rhPSMA-7 PET/CT在根治性原发放疗后前列腺癌生化复发(BCR)患者中的效能。共纳入97例患者,18F-rhPSMA-7在91/97(94%)患者中检出可疑复发灶,各PSA分层检出率分别为88%(22/25,PSA<2 ng/mL)、97%(30/31,2-<5 ng/mL)、90%(19/21,5-<10 ng/mL)和100%(20/20,≥10 ng/mL)。作者结论认为其检出率高,诊断效能与其他已发表的PSMA配体数据相当。
要点
- 18F-rhPSMA-7 PET/CT在放疗后生化复发的前列腺癌患者中总检出率为94%(91/97)。
- PSA<2、2-<5、5-<10、≥10 ng/mL各层检出率分别为88%(22/25)、97%(30/31)、90%(19/21)、100%(20/20)。
- 既往使用与未使用雄激素剥夺治疗(ADT)者检出率无显著差异(100% vs. 91%,P=0.173)。
核心结论
- 18F-rhPSMA-7 PET/CT在原发性放疗后生化复发的前列腺癌患者中显示出高检出率,即使在低PSA值时亦然。
- 其诊断效能与已发表的其他PSMA配体数据相当。
研究设计与样本
- 双中心回顾性分析,纳入在外照射放疗或近距离放疗后出现生化复发、并在慕尼黑工业大学或慕尼黑路德维希-马克西米利安大学接受18F-rhPSMA-7 PET/CT的前列腺癌患者。
- 由两中心经验丰富的核医学医师和放射科医师回顾性阅片,记录所有提示复发的病灶,并将检出率与PSA水平、原发Gleason评分及既往ADT使用进行相关性分析。
- 共纳入97例患者(慕尼黑工业大学65例,慕尼黑路德维希-马克西米利安大学32例),中位注射活度为299 MBq(范围204-420 MBq),中位摄取时间为77分钟(范围46-120分钟)。
主要发现
- 扫描前中位PSA为4.19 ng/mL(范围0.1-159 ng/mL);原发Gleason评分≤6者19例、7者25例、≥8者33例、未知20例;30例在PET/CT前6个月内接受过ADT。
- 18F-rhPSMA-7在91/97(94%)患者中检出病灶;按PSA<2、2-<5、5-<10、≥10 ng/mL分层检出率分别为88%(22/25)、97%(30/31)、90%(19/21)、100%(20/20)。
- 在未满足Phoenix生化复发标准的亚组中,PSA<0.5、0.5-<1、1-<1.5、1.5-2 ng/mL各层检出率分别为80%(4/5)、90%(9/10)、100%(4/4)、83%(5/6)。
- 有与无既往ADT者检出率无显著差异(100% vs. 91%,P=0.173);Gleason评分≤7与≥8者检出率无显著差异(98% vs. 91%,P=0.316)。
- 18F-rhPSMA-7显示局部复发78/97(80%)、盆腔淋巴结转移37/97(38%)、腹膜后淋巴结转移9/97(9%)、膈上淋巴结转移4/97(4%)、骨转移26/97(27%)、内脏转移3/97(3%);在PSA<2 ng/mL且高于最低点的亚组中,局部复发19/25(76%)、盆腔淋巴结转移9/25(36%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This bicentric, retrospective analysis investigated the efficacy of PET/CT with a novel theranostic prostate-specific membrane antigen (PSMA)--targeting ligand, 18F-rhPSMA-7, in patients with biochemical recurrence (BCR) of prostate cancer after curative-intent primary radiotherapy. Methods: Datasets from patients with BCR of prostate cancer after external-beam radiation therapy or brachytherapy who underwent 18F-rhPSMA-7 PET/CT at either Technical University Munich or Ludwig-Maximilians-University Munich were retrospectively reviewed by experienced nuclear medicine physicians and radiologists at both centers. The median injected activity was 299 MBq (range, 204-420 MBq), and the median uptake time was 77 min (range, 46-120 min). All lesions suggestive of recurrent prostate cancer were noted. Detection rates were correlated with patients' prostate-specific antigen (PSA) level, primary Gleason score, and prior use of androgen-deprivation therapy (ADT). Results: Ninety-seven patients were included (65 at Technical University Munich and 32 at Ludwig-Maximilians-University Munich). The median prescan PSA was 4.19 ng/mL (range, 0.1-159 ng/mL). The primary Gleason score was ≤6 in 19 patients, 7 in 25, ≥8 in 33, and unknown in 20. Thirty patients received ADT in the 6 mo preceding PET/CT. 18F-rhPSMA-7 identified lesions in 91 of 97 (94%) patients. Detection rates stratified by PSA were 88% (22/25), 97% (30/31), 90% (19/21), and 100% (20/20) for a PSA of <2, 2-<5, 5-<10, and ≥10 ng/mL, respectively. Detection rates in the subgroup of patients not meeting the Phoenix criteria for BCR were 80% (4/5), 90% (9/10), 100% (4/4), and 83% (5/6) for a PSA of <0.5, 0.5-<1, 1-<1.5, and 1.5-2 ng/mL, respectively. There were no significant differences in detection rates between patients with and without prior ADT (100% vs. 91%, P = 0.173) or patients with a Gleason score of ≤7 and a Gleason score of ≥8 (98% vs. 91%, P = 0.316).18F-rhPSMA-7 revealed local recurrence in 80% (78/97); pelvic lymph node metastases in 38% (37/97); retroperitoneal and supradiaphragmatic lymph node metastases in 9% (9/97) and 4% (4/97), respectively; bone metastases in 27% (26/97); and visceral metastases in 3% (3/97). In the subgroup of patients with a PSA of <2 ng/mL above nadir, local recurrence occurred in 76% (19/25) and pelvic lymph node metastases in 36% (9/25). Conclusion:18F-rhPSMA-7 PET/CT demonstrates high detection rates in prostate cancer patients with BCR after primary radiation therapy, even at low PSA values. Its diagnostic efficacy is comparable to published data for other PSMA ligands.
引用
- Ilhan H, Kroenke M, Wurzer A, et al. 18F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. J Nucl Med. 2022. PMID: 35273094. doi:10.2967/jnumed.121.262861
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。